VERY CHEAP AND BEST MOUSE AT ₹99

-
Image
VERY CHEAP AND BEST MOUSE Mouse Name- Zinq Technologies ZQ233 Wired Mouse with 1000DPI, 10 Million Clicks Lifespan for Laptop and Desktop (Black) M.R.P: ₹299.00 ₹99.00 LINK TO BUY- CLICK HERE FITS EVERY HAND Zinq mouse device is compact that fits right and left both hands comfortably. It has a smooth hand touch on the overall surface of the mouse for comfortable controlling and navigation. The ruff pattern on the top increase grip and reduce sweat.                                                           ARTISTIC DESIGN The Zinq ZQ23 Mouse is artistically designed from its ruff top area to the dotted sides. It is usable in office and home due to its appealing design. MULTI-DEVICE COMPATIBILITY The optical mouse is Compatible with Windows 98/2000/ME/NT/XP/Vista/Linux/WIN10, which gives variability to the user. SMOOTH NAVIGATION The Zinq mouse ...
Post a Comment

Covid-19 Vaccine Update: Biological E completes phase 2 trial, gets nod for phase III trial in India.

-
Covid-19 Vaccine Update: Biological E completes phase 2 trial, gets nod for phase III trial in India.


Hyderabad-based pharma company 'Biological E' has got the approval for Phase 3 clinical trial of its indigenous Covid-19 vaccine. If this vaccine proves to be successful and is approved by the government, India could get its second indigenous vaccine against Covid-19.

BEs novel Covid-19 vaccine was found to be safe and well tolerated and immunogenic, the release said.
Biological E. Limited (BE) on Saturday announced that it has successfully completed Phase I/II clinical trials of its COVID-19 subunit vaccine candidate in India and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organization (CDSCO) – Subject Expert Committee (SEC). BE started the Phase I/II clinical trials of its COVID-19 Vaccine candidate in the second week of November 2020, the vaccine maker said in a press release.

Its candidate includes an antigen developed by the Texas Childrens Hospital Center for Vaccine Development and in-licensed from BCM Ventures, Baylor College of Medicines integrated commercialization team, along with Dynavax Technologies Corporations advanced adjuvant CpG 1018TM. The Coalition for Epidemic Preparedness Innovations (CEPI) and the Biotechnology Industry Research Assistance Council (BIRAC) have provided support for the Phase I/II clinical trials and also for the upcoming Phase III trial of this vaccine candidate, it said.

BE’s Phase I/II clinical trial evaluated the safety and immunogenicity of the vaccine candidate, consisting of the Receptor Binding Domain of the Spike Protein of SARS-CoV-2 at three-dose level adjuvanted with CpG 1018 plus alum, in about 360 healthy subjects in the age range of 18 to 65 years. The vaccination schedule consisted of two doses for each study participant, administered via intramuscular injection 28 days apart.

BEs novel Covid-19 vaccine was found to be safe and well tolerated and immunogenic, the release said. Mahima Datla, Managing Director,BE,said “We are delighted with the success of the Phase I/II clinical trials of our COVID-19 vaccine candidate. The results of these clinical trials are very positive and promising.

We believe that our vaccine candidate will become another effective global COVID-19 vaccine as we move forward into Phase III clinical trials.” The Phase III clinical study to be conducted in 15 sites across India will evaluate the Immunogenicity and Safety of BEs SARS-CoV-2 COVID-19 vaccine for protection against COVID-19 in about 1268 healthy subjects in the age range of 18 to 80 years. It is intended to be part of a larger global Phase III study, the release said.

Hyderabad, Apr 24: Biological E. Limited (BE) on Saturday announced that it has successfully completed Phase I/II clinical trials of its COVID-19 subunit vaccine candidate in India and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organization (CDSCO) - Subject Expert Committee (SEC).

BE started the Phase I/II clinical trials of its COVID-19 Vaccine candidate in the second week of November 2020, the vaccine maker said in a press release. 

Its candidate includes an antigen developed by the Texas Childrens Hospital Center for Vaccine Development and in- licensed from BCM Ventures, Baylor College of Medicines integrated commercialization team, along with Dynavax Technologies Corporations advanced adjuvant CpG 1018TM.

The Coalition for Epidemic Preparedness Innovations (CEPI) and the Biotechnology Industry Research Assistance Council (BIRAC) have provided support for the Phase I/II clinical trials and also for the upcoming Phase III trial of this vaccine candidate, it said.

BE's Phase I/II clinical trial evaluated the safety and immunogenicity of the vaccine candidate, consisting of the Receptor Binding Domain of the Spike Protein of SARS-CoV-2 at three-dose level adjuvanted with CpG 1018 plus alum, in about 360 healthy subjects in the age range of 18 to 65 years.

Covid vaccine for all above 18: Centre's fresh guidelines for states ahead of Phase 3 Covid vaccine for all above 18: Centre's fresh guidelines for states ahead of Phase 3

The vaccination schedule consisted of two doses for each study participant, administered via intramuscular injection 28 days apart.

BEs novel Covid-19 vaccine was found to be safe and well tolerated and immunogenic, the release said.

Mahima Datla, Managing Director,BE,said 'We are delighted with the success of the Phase I/II clinical trials of our COVID-19 vaccine candidate.

The results of these clinical trials are very positive and promising.

We believe that our vaccine candidate will become another effective global COVID-19 vaccine as we move forward into Phase III clinical trials.' The Phase III clinical study to be conducted in 15 sites across India will evaluate the Immunogenicity and Safety of BEs SARS-CoV-2 COVID-19 vaccine for protection against COVID-19 in about 1268 healthy subjects in the age range of 18 to 80 years.

It is intended to be part of a larger global Phase III study, the release said.


For more blog visit here.


Comments

Post a Comment

Popular posts from this blog

Hindu Temple Part.3

-
Image
Forms and designs of Hindu temples Almost all Hindu temples take two forms:a house or a palace. A house-themed temple is a simple shelter which serves as a deity's home. The temple is a place where the devotee visits, just like he or she would visit a friend or relative. The use of moveable and immoveable images is mentioned by Pāṇini. In Bhakti school of Hinduism, temples are venues for puja, which is a hospitality ritual, where the deity is honored, and where devotee calls upon,attends to and connects with the deity. In other schools of Hinduism, the person may simply perform jap, or meditation, or yoga,or introspection in his or her temple.Palace-themed temples often incorporate more elaborate and monumental architecture. Site The appropriate site for a temple, suggest ancient Sanskrit texts, is near water and gardens, where lotus and flowers bloom, where swans, ducks and other birds are heard, where animals rest without fear of injury or harm.These harmonious places...
Read more

Hindu Temple Part. 4

-
Image
The Silpa Prakasa of Odisha, authored by Ramacandra Bhattaraka Kaulacara in the ninth or tenth centuries AD, is another Sanskrit treatise on Temple Architecture. Silpa Prakasa describes the geometric principles in every aspect of the temple and symbolism such as 16 emotions of human beings carved as 16 types of female figures. These styles were perfected in Hindu temples prevalent in eastern states of India. Other ancient texts found expand these architectural principles, suggesting that different parts of India developed, invented and added their own interpretations. For example, in Saurastra tradition of temple building found in western states of India, the feminine form, expressions and emotions are depicted in 32 types of Nataka-stri compared to 16 types described in Silpa Prakasa.Silpa Prakasa provides brief introduction to 12 types of Hindu temples.Other texts, such as Pancaratra Prasada Prasadhana compiled by Daniel Smith and Silpa Ratnakara compiled by Narmada Sanka...
Read more

ABOUT COVID-19 VACCINES

-
Image
 The COVID-19 outbreak has shaken the global health system and economy by its roots. This epidemic is continuously spreading and showing no signs of slowing down. Vaccination could be the only effective and economical means to control or stop this pandemic. Many research institutions and pharmaceutical companies worldwide are currently involved in the development of a suitable coronavirus vaccine. What are the Stages of development for a covid 19 Vaccine? The development of coronavirus vaccines consists of the following steps e.g. exploratory, pre-clinical and clinical stages. 1. Exploratory stage – It is the basic research in the laboratory of the conceptual idea and development of an antigen against the disease against which a vaccine needs to be produced which usually takes 2–4 years’ timeframe. 2. Pre-clinical stage of development – It uses a platform of tissue-culture and animal testing to assess the safety of the vaccine. They may also suggest the safest starting dose for t...
Read more